Bristol-Myers Squibb to acquire Mirati Therapeutics for $58 per share
08/10/2023 22:30
Oct 8 (Reuters) - Bristol-Myers Squibb BMY.N to acquire Mirati Therapeutics MRTX.O for $58 per share, representing $4.8 billion equity value. (Reporting by Dimpal Gulwani; Editing by Lisa Shumaker) ((Dimpal.Gulwani@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)